Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer

BACKGROUND: Oncogenic KRAS mutations are prevalent in human cancers, but effective treatment of KRAS-mutant malignancies remains a major challenge in the clinic. Increasing evidence suggests that aberrant metabolism plays a central role in KRAS-driven oncogenic transformation. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhang, Liang, Shun-Qing, Zhao, Liang, Yang, Haitang, Marti, Thomas M., Hegedüs, Balazs, Gao, Yanyun, Zheng, Bin, Chen, Chun, Wang, Wenxiang, Dorn, Patrick, Kocher, Gregor J., Schmid, Ralph A., Peng, Ren-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762933/
https://www.ncbi.nlm.nih.gov/pubmed/35039048
http://dx.doi.org/10.1186/s13046-022-02240-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762933/
https://www.ncbi.nlm.nih.gov/pubmed/35039048
http://dx.doi.org/10.1186/s13046-022-02240-5

Ejemplares similares